Recent announcements on the COVID-19 front:
Luminex (NASDAQ:LMNX): Working on two SARS-Cov-2 tests:
NxTAG CoV Expanded Panel: should be available to ship to customers in a
few weeks. Testing in China to wind up in the next several days.
Testing in U.S. underway. SARS-CoV-2 on ARIES real-time PCR system:
company has evaluated a single-target test for SARS-CoV-2 while two
European reference labs successfully validated a multi-targeted test
under Emergency Use Authorization from the FDA. CEO Nachum Shamir says
it is premature to quantify the financial impact of these efforts.
Arcturus Therapeutics (NASDAQ:ARCT): Partnering with Duke-NUS Medical School on COVID-19 vaccine for Singapore (based on STARR technology).
AIM ImmunoTech (NYSEMKT:AIM): Partnering with ChinaGoAbroad to facilitate the entry of Ampligen into China to be used as a prophylactic/early-onset therapeutic against COVID-19.
LMNX up 3% premarket. ARCT up 28%. AIM up 22%.
https://seekingalpha.com/news/3548511-and-covidminus-19-list-keeps-growing
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.